All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML). Treatment of pediatric APL is based on the combination of all-trans-retinoic acid (ATRA), an anthracycline and cytosine arabinoside. Arsenic trioxide (ATO) has been studied in adults with newly diagnosed or relapsed APL with excellent response rates both when used as a single agent or in combination with ATRA or ATRA plus chemotherapy. There is little data on combination therapy with ATRA and ATO in pediatric APL. We present a case of an adolescent male with APL who was treated using ATRA and ATO without conventional chemotherapy agents.
Quezada
Gerardo
G
Texas Transplant Institute, 7711 Louis Pasteur Drive, Suite 708, San Antonio, Texas 78229, USA.
Kopp
Lisa
L
Estey
Elihu
E
Wells
Robert J
RJ
D000293:Adolescent; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004416:Dysplastic Nevus Syndrome; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D010087:Oxides / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use*
D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide